HPV vaccine not cost-effective for adults age 26 to 45, study finds
Vaccination against human papillomavirus provides limited health benefits for adults aged 26 years and older at a high cost to the healthcare system, according to a study published Thursday by PLOS Medicine.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
More News: Cervical Cancer Vaccine | Genital Warts | Health | Human Papillomavirus (HPV) | Study | Vaccines